Abstract:Gliomas, and in particular glioblastoma multiforme, are aggressive brain tumors characterized by a poor prognosis and high rates of recurrence. Current treatment strategies are based on open surgery, chemotherapy (temozolomide) and radiotherapy. However, none of these treatments, alone or in combination, are considered effective in managing this devastating disease, resulting in a median survival time of less than 15 months. The efficiency of chemotherapy is mainly compromised by the blood-brain barrier (BBB) that selectively inhibits drugs from infiltrating into the tumor mass. Cancer stem cells (CSCs), with their unique biology and their resistance to both radio- and chemotherapy, compound tumor aggressiveness and increase the chances of treatment failure. Therefore, more effective targeted therapeutic regimens are urgently required. In this article, some well-recognized biological features and biomarkers of this specific subgroup of tumor cells are profiled and new strategies and technologies in nanomedicine that explicitly target CSCs, after circumventing the BBB, are detailed. Major achievements in the development of nanotherapies, such as organic poly(propylene glycol) and poly(ethylene glycol) or inorganic (iron and gold) nanoparticles that can be conjugated to metal ions, liposomes, dendrimers and polymeric micelles, form the main scope of this summary. Moreover, novel biological strategies focused on manipulating gene expression (small interfering RNA and clustered regularly interspaced short palindromic repeats [CRISPR]/CRISPR associated protein 9 [Cas 9] technologies) for cancer therapy are also analyzed. The aim of this review is to analyze the gap between CSC biology and the development of targeted therapies. A better understanding of CSC properties could result in the development of precise nanotherapies to fulfill unmet clinical needs.

How Nanotherapeutic Platforms Play a Key Role in Glioma? A Comprehensive Review of Literature

Interpreting the Therapeutic Efficiency of Multifunctional Hybrid Nanostructure Against Glioblastoma

Glioma nanomedicine: Design, fabrication and theranostic application

Contemporary strategies in glioblastoma therapy: Recent developments and innovations

Potential of Nanocarrier-Associated Approaches for Better Therapeutic Intervention in the Management of Glioblastoma

Advances in blood–brain barrier-crossing nanomedicine for anti-glioma

Nanoparticles for efficient drug delivery and drug resistance in glioma: New perspectives

Glioma diagnosis and therapy: Current challenges and nanomaterial-based solutions

Blood-Brain Barrier Conquest in Glioblastoma Nanomedicine: Strategies, Clinical Advances, and Emerging Challenges

Targeted Regulation of Blood-Brain Barrier for Enhanced Therapeutic Efficiency of Hypoxia-Modifier Nanoparticles and Immune Checkpoint Blockade Antibodies for Glioblastoma

Advances in nanotechnology for the treatment of GBM

Nanomedicine facilitated cell signaling blockade: difficulties and strategies to overcome glioblastoma

Nanotechnology as a new strategy for the diagnosis and treatment of gliomas

Combined-therapeutic strategies synergistically potentiate glioblastoma multiforme treatment via nanotechnology

Application of Cell Membrane-Functionalized Biomimetic Nanoparticles in the Treatment of Glioma

Applications of nanotechnology in remodeling the tumour microenvironment for glioblastoma treatment

Nanomedicines Targeting Glioma Stem Cells

Functionalized nanoparticles crossing the brain–blood barrier to target glioma cells

Targeted Nanotechnology in Glioblastoma Multiforme

The Nanocarrier Strategy for Crossing the Blood-Brain Barrier in Glioma Therapy

Emerging Blood-Brain-barrier-crossing Nanotechnology for Brain Cancer Theranostics.